Page last updated: 2024-08-24

topotecan and Local Neoplasm Recurrence

topotecan has been researched along with Local Neoplasm Recurrence in 294 studies

Research

Studies (294)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	23 (7.82)	18.2507
2000's	147 (50.00)	29.6817
2010's	107 (36.39)	24.3611
2020's	17 (5.78)	2.80

Authors

Authors	Studies
Agar, NYR; Al-Dalahmah, O; Argenziano, MG; Banu, MA; Behl, M; Boyett, DM; Bruce, JN; Canoll, P; Catania, V; D'Amico, RS; Furnari, JL; Gill, BJA; Good, L; Grinband, J; Higgins, DMO; Humala, N; Iwamoto, FM; Jambawalikar, S; Lassman, AB; Lignelli, A; Mahajan, A; Marie, T; Mintz, A; Neira, JA; Pereira, B; Petridis, P; Regan, MS; Save, AV; Sims, PA; Spinazzi, EF; Stopka, SA; Sudhakar, TD; Upadhyayula, PS; Welch, MR; Wu, PB; Zacharoulis, S; Zhao, W	1
Bhosale, P; Chisholm, GB; Flores-Legarreta, A; Frumovitz, M; Gonzales, NR; Hillman, RT; Jhingran, A; Ramalingam, P; Salvo, G	1
Arndt, T; Belau, AK; Braicu, EI; Canzler, U; Chekerov, R; de Gregorio, N; Mahner, S; Mustea, A; Neunhoeffer, T; Pietzner, K; Richter, R; Sehouli, J; Stocker, G; Strauß, HG; von Abel, E; Wimberger, P; Woelber, L; Yalinkaya, I	1
Aljumaily, R; Burris Iii, HA; Johnson, ML; Jones, SF; Patel, MR; Spigel, DR	1
Badel, JN; Bogart, E; Corradini, N; Cougnenc, O; Courbon, F; Defachelles, AS; Deley, MCL; Gambart, M; Giraudet, AL; Kolesnikov-Gauthier, H; Oudoux, A; Rault, E; Schleiermacher, G; Sevrin, F; Valteau-Couanet, D	1
Carta, R; Cefalo, MG; D'Andrea, ML; De Ioris, MA; Del Baldo, G; Del Bufalo, F; Fabozzi, F; Garganese, MC; Giovannoni, I; Greco, AM; Locatelli, F; Mastronuzzi, A; Stracuzzi, A; Tangari, F; Villani, MF	1
Bergamini, A; Bocciolone, L; Candiani, M; Fodor, A; Mangili, G	1
Alvarez Secord, A; Armstrong, DK; Azab, M; Banerjee, S; Basu, B; Birrer, MJ; Blagden, SP; Braly, P; Fleming, GF; Ghamande, S; Hall, GD; Hao, Y; Hirte, HW; Jueliger, S; Keer, H; Kristeleit, R; Markham, MJ; Matei, D; Matulonis, UA; McGuire, WP; Naim, S; Nemunaitis, J; Nephew, KP; Oganesian, A; Oza, AM; Provencher, DM; Roman, LD; Schwartz, B	1
Chang, J; Li, YN; Liu, ZL; Yao, YM; Zhang, YT; Zhong, XD	1
Capra, M; Chew, S; Daly, P; Gleeson, JP; Grant, C; McCarthy, A; McDermott, M; Nicholson, S; O'Dwyer, R; Owens, C; Watson, GA	1
Besse, B; Blackhall, F; Califano, R; Cappuzzo, F; de Marinis, F; De Ruysscher, D; Felip, E; Früh, M; Garrido, P; Novello, S; O'Brien, M; Panje, CM; Paz Ares, L; Putora, PM; Reck, M; Westeel, V	1
Aghajanian, C; Banerjee, S; Berger, R; Boyd, AP; Christy-Bittel, J; Churruca, C; Cibula, D; Clamp, A; Coleman, RL; Colombo, N; Del Campo, JM; Drill, E; Grisham, RN; Hilpert, F; Kalbacher, E; Kristensen, G; Marth, C; Mirza, MR; Monk, BJ; Moore, KN; O'Malley, DM; Oehler, MK; Oza, AM; Pignata, S; Ray-Coquard, I; Romero, I; Sehouli, J; Vergote, I; Vuylsteke, P; Westermann, A	1
Li, X; Lu, S; Ma, J; Tanumiharjo, S; Xing, Y; Yu, X	1
Arrieta, O; Lara-Mejía, L; Zatarain-Barrón, ZL	1
Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS	1
Chen, H; Horita, N; Takeshi, K	1
Baize, N; Chouaid, C; Monnet, I	1
Guerra, I; McCormack, M; Munk, VC; Nogueira-Rodrigues, A; Rosen, VM; Sasse, A; Shang, A	1
Bonnetain, F; de la Motte Rouge, T; Kalbacher, E; Lesoin, A; Pautier, P	1
Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U	1
Li, Q; Sun, L; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K	1
Beck-Popovic, M; Gaillard, MC; Hadjistilianou, D; Maeder, P; Munier, FL; Puccinelli, F; Stathopoulos, C	1
Choi, YS; Jo, DY; Kim, JM; Ko, YB; Lee, HJ; Ryu, H; Song, IC; Yun, HJ	1
Ko, YB; Lee, HJ; Moon, JY; Song, IC	1
Ceciliano, A; Chantada, GL; Fandiño, A; Funes, S; Lagomarsino, E; Manzitti, J; Neira, P; Peralta, L; Sampor, C; Schaiquevich, P; Sgroi, M; Villasante, F	1
Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T	1
Corrado, G; Ferrandina, G	1
Hjortkjær, M; Jakobsen, A; Kanstrup, H; Steffensen, KD	1
Choi, MC; Jeong, DH; Kang, S; Kim, JW; Kim, KH; Kim, TH; Kim, YB; Kim, YM; Lee, IH; Lee, JW; Lee, JY; Lee, KB; Lee, YJ; Park, JY; Park, SY; Pujade-Lauraine, E	1
Beaumont, H; Chadjaa, M; Evans, TL; Guermazi, A; Hong, SR; Klifa, C; Monostori, Z	1
Nazha, B; Owonikoko, TK	1
Kim, JC; Kim, JH; Kim, YM; Yoon, YS	1
Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Kouroussis, C; Polyzos, A; Syrios, J; Vardakis, N	1
Echebarria, A; Genolla, J; Llorens, V; Lopez-Almaraz, R; Minguez, P; Rodriguez, T	1
Braicu, EI; Canaz, E; Chekerov, R; Grabowski, JP; Richter, R; Sehouli, J	1
Ahmad, M; Akhlaq, M; Danish, Z; Saeed, H; Saleem, Z; Sattar, S	1
Alavi, S; Chekerov, R; Inci, G; Richter, R; Sehouli, J; Woopen, H	1
Lin, B; Shao, L; Song, Z; Zhang, Y	1
Atlas, I; Barak, F; Berman, T; Bruchim, I; Levy, T; Meirovitz, M; Rosengarten, OS; Safra, T; Yachnin, A	1
Agaoglu, FY; Cakir, FB; Darendeliler, E; Gorgun, O; Kebudi, R	1
Alvarez Secord, A; Case, AS; Cohn, DE; Dehdashti, F; Eisenhauer, EL; Gao, F; Lippmann, LT; Massad, LS; Mutch, DG; Powell, MA; Rader, JS; Thaker, PH; Valea, FA; Wright, JD; Zighelboim, I	1
Agelaki, S; Bompolaki, I; Chandrinos, V; Georgoulias, V; Kalbakis, K; Kontopodis, E; Kotsakis, A; Papadimitraki, E; Stoltidis, D; Zafeiriou, Z	1
Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; McCann, GA; O'Malley, DM; Richardson, DL; Salani, R; Smith, B	1
Ashraf, K; Baruchel, S; Gibson, P; Irwin, MS; Shaikh, F	1
Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP	1
Cao, H; Chen, X; Chen, Y; Fan, J; Fu, S; Lin, S; Ren, P; Su, Z; Sun, X; Wu, J; Yang, B; Yang, L; Zhang, Y; Zhou, J; Zhou, Y; Zou, X	1
Finlay, JL; Gardner, S; Liebes, LF; Tran, HC; Weiner, HL	1
Aerts, I; Amoroso, L; Boubaker, A; Casanova, M; Chastagner, P; Courbon, F; Devos, A; Di Giannatale, A; Dias-Gastellier, N; Ducassoul, S; Geoerger, B; Landman-Parker, J; Le Deley, MC; Malekzadeh, K; Mc Hugh, K; Munzer, C; Riccardi, R; Rubie, H; Verschuur, A; Zwaan, CM	1
Curtin, J; Downey, A; Edwards, S; Kwa, M; Muggia, F; Reich, E; Wallach, R	1
Huang, H; Landrum, LM; Leitao, MM; Long, HJ; Michael, HE; Monk, BJ; Oaknin, A; Penson, RT; Ramondetta, LM; Reid, TJ; Sill, MW; Tewari, KS	1
Abu-Khalaf, MM; Acevedo-Gadea, C; Azodi, M; Higgins, SA; Ratner, E; Rutherford, T; Santin, AD; Schwartz, PE; Silasi, DA; Urva, S	1
Bamias, A; Bollag, D; Follana, P; Hilpert, F; Kristensen, G; Mirza, MR; Oaknin, A; Pereira, D; Poveda, A; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Sorio, R; Vergote, I; Weber, B; Wimberger, P; Witteveen, P	1
Barron, R; Chandler, DB; Fust, K; Li, X; Lyman, GH; Maschio, M; Parthan, A; Walli-Attaei, M; Weinstein, MC	1
Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q	1
Eskander, RN; Tewari, KS	1
Ardizzoni, A; Boni, L; Tiseo, M	1
Adewoye, H; Ananda, S; Bass, MB; Dirix, L; Gordon, AN; Kridelka, F; Leach, JW; Litten, J; Melara, R; Nanayakkara, N; Pippitt, CH; Schilder, RJ; Scudder, S; Vergote, I; Wenham, RM; Wong, S	1
Kamimura, S; Moritake, H; Nunoi, H; Takeshima, H; Yamada, A; Yamashita, S	1
Acha, T; Bergeron, C; Catania, S; Graf, N; Howell, L; Mavinkurve-Groothuis, AM; Pritchard-Jones, KL; Spreafico, F; Tytgat, GA; van den Heuvel-Eibrink, MM; van Tinteren, H; Vujanic, G	1
Bender, DP; Carter, JS; Dawson, D; Deng, W; Gray, HJ; Guaglianone, PP; Kunos, C; Lea, JS; Moore, KN; Zanotti, KM	1
Barton, S; Edwards, SJ; Thurgar, E; Trevor, N	1
Huang, HQ; Landrum, LM; Leitao, MM; Long, HJ; Method, M; Michael, H; Monk, BJ; Oaknin, A; Penson, RT; Ramondetta, LM; Reid, TJ; Stockman, S; Tewari, KS; Wenzel, LB	1
Krill, LS; Tewari, KS	1
Chang Chien, CC; Fu, HC; Hu, CF; Lin, H; Ou, YC; Tsai, CC; Wu, CH	1
Matsumoto, K; Onda, T; Yaegashi, N	1
Du, XL; Li, L; Shan, CP; Sheng, XG; Wei, P; Zhang, ZH	1
Cao, C; Jabbour, PM; Pointdujour-Lim, R; Say, EA; Shields, CL; Shields, JA	1
Bongiovanni, A; Burgio, MA; Califano, R; Carloni, F; Casanova, C; Cavallo, G; Di Battista, M; Genestreti, G; Kazushige, W; Kenmotsu, H; Korkmaz, T; Metro, G; Roopa, K; Scarpi, E; Selcuk, S; Tiseo, M	1
Enomoto, Y; Hasegawa, H; Imokawa, S; Inui, N; Karayama, M; Matsui, T; Ozawa, Y; Suda, T; Yokomura, K	1
Bevis, KS; Blansit, K; Chan, JK; ElNaggar, A; Fuh, KC; Huh, W; Kapp, DS; Previs, R; Secord, AA; Tillmanns, T	1
Grünwald, V; Hartmann, JT; Hertenstein, B; Issels, RD; Krause, S; Nicolo, KS; Papesch, E; Sturm, I	1
Bamias, A; Hilpert, F; Mitchell, L; Poveda, AM; Pujade-Lauraine, E; Reuss, A; Savarese, A; Scotto, N; Selle, F; Vergote, I; Witteveen, P	1
Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB	1
Horita, N; Inoue, M; Kaneko, T; Kudo, M; Nagai, K; Nagakura, H; Nakashima, K; Sato, T; Shibata, Y; Shinkai, M; Tashiro, K; Tsukahara, T; Ushio, R; Watanabe, H; Yamamoto, M	1
Casaluce, F; Gridelli, C; Maione, P; Palazzolo, G; Rossi, A; Sacco, PC; Santabarbara, G; Sgambato, A	1
Hanvoravongchai, P; Havanond, P; Khempech, N; Luealon, P; Vasuratna, A	1
Carpentier, P; Clisant, S; Cougnenc, O; Defachelles, AS; Kolesnikov-Gauthier, H; Lervat, C; Oudoux, A	1
Ben-Harim, Z; Bruchim, I; Fishman, A; Haran, G; Piura, E	1
Goto, K; Hida, T; Imamura, F; Kiura, K; Kozuki, T; Mori, K; Nakagawa, K; Nishio, M; Ohe, Y; Okamoto, H; Satouchi, M; Sawa, T; Seto, T; Shibata, T; Takahashi, T; Takeda, K; Tamura, T; Tanaka, H; Yoshimura, N	1
Hasanreisoglu, M; Iyer, PG; Jabbour, P; Lally, SE; Say, EA; Shields, CL; Shields, JA	1
Fuller, DG; Jabbour, PM; Khoo, CT; Magan, T; Shields, CL	1
Amoroso, L; Bautista, F; Chevance, A; Gambart, M; Garaventa, A; Geoerger, B; Le Deley, MC; Moreno, L; Paoletti, X; Pearson, AD; Rubie, H; Valteau-Couanet, D; Varo, A; Vassal, G	1
Alistar, A; Bonomi, M; Chan, MD; Isom, S; Lamar, ZS; Lycan, TW; Miller, AA; Pardee, TS; Petty, WJ; Ruiz, J	1
Belau, AK; Bover-Barcelo, I; Canzler, U; Chekerov, R; Gonzalez-Martin, A; Hanker, LC; Harter, P; Hilpert, F; Keil, E; Klare, P; Kurzeder, C; Mahner, S; Meier, W; Petru, E; Reinthaller, A; Richter, R; Sehouli, J; Wimberger, P; Woopen, H; Zeimet, A	1
Allen, S; DuBois, SG; Gustafson, WC; Hollinger, F; Karski, EE; Long-Boyle, JR; Matthay, KK; Nasholm, NM; Shiboski, S; Vo, KT	1
Brown, J; Burzawa, JK; Byers, LA; Coleman, RL; Frumovitz, M; Munsell, MF; Ramalingam, P	1
Coeffic, D; García, Y; Gebski, V; Gibbs, E; González-Martín, A; Hilpert, F; Huizing, M; Kaern, J; Kristensen, G; Lee, CK; Levaché, CB; Lück, HJ; Pujade-Lauraine, E; Roemer-Becuwe, C; Sorio, R; Witteveen, P; Zagouri, F	1
Goff, BA; Holmberg, LA; Kurland, BF; Veljovich, D	1
Camara, O; Keil, E; Klare, P; Lichtenegger, W; Oskay-Oezcelik, G; Paulenz, A; Sehouli, J; Sommer, H; Stauch, M; Stengel, D; Zeimet, AG	1
Eisenkop, SM; McAlpine, JN; Spirtos, NM	1
Aravantinos, G; Bafaloukos, D; Bamias, A; Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Papadimitriou, CA; Pectasides, D	1
Kamposioras, K; Papaxoinis, G; Pectasides, D; Pectasides, E	1
Biassoni, V; Casanova, M; Catania, S; Favini, F; Ferrari, A; Luksch, R; Meazza, C; Morosi, C; Podda, M; Zaffignani, E	1
Budning, A; Chan, HS; Dai, S; Dimaras, H; Doyle, J; Drake, J; Gallie, BL; Halliday, W; Héon, E	1
Havlioglu, N; Hueser, CN; Nguyen, NC; Osman, M; Patel, AJ	1
Antras, L; Chen, L; Duh, MS; Neary, M; O'Brien, ME	1
Coleman, RL; Gibb, RK; Herzog, TJ; Lippmann, L; Mutch, DG; Powell, MA; Rader, JS	1
Arias, D; Candelaria, M; Cantu, D; Cetina, L; Coronel, J; Dueñas-González, A; González-Fierro, A	1
Fukuoka, M; Kashii, T; Kobayashi, M; Kurata, T; Nakagawa, K; Satoh, T; Seki, N; Takeda, K; Tsuboi, M	1
Griffin, D; Hunter, JE; Phillips, B; Puls, LE; Schammel, C	1
Angioli, R; Arrivi, C; Basile, S; Bellati, F; Calcagno, M; Palaia, I; Panici, PB; Pastore, M; Plotti, F; Sansone, M	1
Chekerov, R; Fotopoulou, C; Karavas, A; Lichtenegger, W; Sehouli, J; Trappe, R	1
du Bois, A; Gropp, M; Kimmig, R; Kuhn, W; Lück, HJ; Meier, W; Olbricht, S; Pfisterer, J; Reuss, A; Richter, B	1
Bae, DS; Choi, CH; Kang, H; Kim, BG; Kim, TJ; Lee, JW; Lee, YY	1
Ji, W; Lü, JM; Ou, GF; Ren, H; Wang, LH; Wang, XZ; Yin, WB; Zhou, ZM	1
Benda, J; Boardman, CH; Cella, D; Cohn, DE; McMeekin, DS; Monk, BJ; Ramondetta, LM; Sill, MW	1
Markman, M	1
Fennell, DA; Hurwitz, JL; McCoy, F; Scullin, P	1
Castellano, A; Cialfi, S; De Ioris, MA; De Laurentis, C; De Pasquale, MD; Dominici, C; Donfrancesco, A; Ilari, I; Jenkner, A; McDowell, HP	1
Yamanaka, R	1
Leath, CA; Phippen, NT	1
Boulad, F; Dunkel, IJ; Gilheeney, SW; Khakoo, Y; Souweidane, M; Wolden, S	1
Al-Kadhimi, Z; Chow, W; Doroshow, JH; Frankel, P; Leong, L; Lim, D; Mamelak, A; Margolin, K; Morgan, RJ; Shibata, S; Somlo, G; Synold, T; Twardowski, P; Yen, Y	1
Chung, HH; Kang, S; Kang, SB; Kim, HS; Kim, JW; Park, NH; Seo, SS; Song, YS	1
Fleming, GF; Temkin, SM; Yamada, SD	1
Alvarez, RD; Bryant, CS; Deppe, G; Kumar, S; Morris, RT; Munkarah, AR; Shah, JP; Spannuth, W	1
Monk, BJ; Tewari, KS	1
Biernacka, B; Buczkowski, J; Krawczyk, P; Milanowski, J; Perzyło, K; Siwiec, A	1
Eastwood, A; Manca, A; Misso, K; Palmer, S; Paton, F; Paulden, M; Saramago, P	1
Aerts, I; Chastagner, P; Chatelut, E; Corradini, N; Dias, N; Djafari, L; Frappaz, D; Gentet, JC; Geoerger, B; Landman-Parker, J; Le Deley, MC; Leblond, P; Ndiaye, A; Paci, A; Pasquet, M; Rubie, H; Schmitt, A; Vassal, G	1
Bae, DS; Choi, CH; Kim, BG; Kim, MK; Kim, TJ; Lee, JH; Lee, JW; Lee, YY; Park, HS; Song, TJ	1
Bird, A; Clegg, A; Harris, P; Hartwell, D; Jones, J; Loveman, E	1
Bashir, Z; Gooch, CL; Kleijnen, J; Riemsma, R; Simons, JP	1
Brainerd, V; Chinnasami, B; Fain, J; Fidias, P; Heist, RS; Khan, W; Leopold, L; Lynch, TJ; Molina, JR; Sequist, LV; Temel, JS	1
Benda, J; Boardman, CH; Cella, D; Cohn, D; Huang, HQ; McMeekin, DS; Monk, BJ; Ramondetta, L; Wenzel, L	1
Aoki, D; Fujiwara, K; Hatae, M; Hiura, M; Kamiura, S; Katsumata, N; Kigawa, J; Nakanishi, T; Noda, K; Ochiai, K; Sugiyama, T; Takehara, K	1
Hartney, J; Lane, S; Legenne, P; Monk, BJ; Provencher, D; Rose, PG	1
DeBernardo, RL; DeGeest, K; Herzog, TJ; Lentz, SS; Mutch, D; O'Malley, D; Shahin, M; Sill, MW; Walker, JL; Weiner, SA	1
Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D	1
Babyn, P; Chan, HS; Dimaras, H; Doyle, J; Gallie, BL; Halliday, W; Héon, E; Paton, KE; Strahlendorf, C	1
Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A	1
Alexandre, J; Dauba, J; Durando, X; Gladieff, L; Largillier, R; Lortholary, A; Paraiso, D; Pujade-Lauraine, E; Slama, B; Weber, B	1
Camporeale, A; Cormio, G; De Mitri, P; Gissi, F; Leone, L; Loizzi, V; Putignano, G; Selvaggi, L	1
Arrowsmith, ER; Burris, HA; Clark, BL; Greco, FA; Hainsworth, JD; Shipley, DL; Spigel, DR; Whorf, RC	1
Bonar, J; Chaber, R; Chybicka, A; Muszynska-Roslan, K; Rygier, J; Wrobel, G	1
Fusco, E; Lorusso, D; Mainenti, S; Malaguti, P; Masciullo, V; Pietragalla, A; Scambia, G	1
Adamson, PC; Berg, S; Blaney, SM; Ingle, AM; Krailo, M; Potter, SL	1
Callahan, M; Johnson, CS; Jones, T; Matei, D; Perkins, SM; Ramasubbaiah, R; Schilder, J; Sutton, G; Whalen, C	1
Alici, S; Altinbas, M; Arpaci, E; Camci, C; Gumus, M; Kalender, ME; Kaplan, MA; Karaca, H; Oven, B; Sevinc, A; Uncu, D; Yildiz, R	1
Ceciliano, A; Chantada, GL; Dominguez, J; Fandino, AC; Millan, N; Schaiquevich, P; Taich, P; Villasante, F	1
Abboud, M; Eid, T; El-Solh, H; Farhat, R; Feghaly, J; Khoury, NJ; Muwakkit, S; Raad, R; Saab, R	1
Katsumata, N; Maejima, A	1
Kitao, A; Matsumoto, K	1
Bally, MB; Osooly, M; Patankar, NA; Pritchard, J; van Grinsven, M	1
Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Wakuda, K; Yamamoto, N	1
Bhatt, K; Lane, S; Legenne, P; Spigel, DR; Waterhouse, DM	1
Fife, K; Gordon, MS; Hanna, NH; Sandler, AB	1
Beshara, N; Faught, W; Fung Kee Fung, M	1
Herzog, TJ	2
Morris, R; Munkarah, A	1
Fiorica, JV	1
Blohmer, J; Camara, O; Elling, D; Heinrich, G; Hindenburg, HJ; Klare, P; Ledwon, P; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D	1
Alvarez, R; Beran, M; Cortes, J; Estey, E; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, AM	1
Blessing, JA; Lentz, SS; Miller, DS; Waggoner, SE	1
Brown, JV; Drescher, CW; Graham, CL; Micha, JP; Peters, WA; Rettenmaier, MA; Smith, MR	1
Goldberg, G; Levy, DE; Lincoln, ST; Schink, JC; Soori, GS; Wadler, S	1
Chiappori, A; Rocha Lima, CM	1
Coldman, BJ; Fossella, FV; Glisson, BS; Komaki, R; Kurie, JM; Lee, JS; Lu, C; Palmer, JL; Pisters, KM; Shin, DM	1
Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D	2
Cheung, NK; Kramer, K; Kushner, BH	1
Casado, A; Casado, MA; de Sande, LM; Merino, P; Ojeda, B	1
Blessing, JA; Lentz, SS; McMeekin, DS; Miller, DS	1
Lane, SR; Ross, GA; ten Bokkel Huinink, W	1
Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C; Høgdall, EV	1
Aquino, VM; Bash, RO; Bowers, DC; Haynes, HJ; Journeycake, JM; Leavey, PJ; Mulne, AF; Tomlinson, G; Winick, NJ	1
Huang, J; Kandel, JJ; Kim, ES; Manley, CA; McCrudden, KW; Middlesworth, W; New, T; O'Toole, K; Soffer, SZ; Yamashiro, DJ	1
Brafman, LB; Hershman, DL; Resnik, EE; Selleck, MJ; Shriberg, L; Smith, D; Tiersten, AD; Troxel, AB	1
Pfisterer, J	1
Aghajanian, C; Ben-Porat, L; Chi, DS; Hensley, ML; Hoppe, B; Prasad, M; Sabbatini, P	1
Huang, CH; Lane, SR; Levin, J; Treat, J	1
Castellano, A; Cozza, R; De Laurentis, C; De Sio, L; Deb, G; Dominici, C; Donfrancesco, A; Fidani, P; Ilari, I; Inserra, A; Jenkner, A; Milano, GM	1
Gibb, RK; Herzog, TJ; Horowitz, NS; Hua, J; Mutch, DG	1
Christensen, IJ; Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C	1
Gordon, AN; Rackoff, W; Sun, S; Tonda, M	1
Aghajanian, C; Dupont, J; Sabbatini, P; Traina, TA	1
Alvarez, RD; Bhoola, SM; Bryant, C; Coleman, RL; Estes, JM; Herzog, T; Morris, R	1
Glezerman, M; Grisaru, D; Inbar, M; Levy, T; Menczer, J; Safra, T	1
Ardizzoni, A	1
Eckardt, JR	1
Anand, A; Chan, SY	1
Choi, M; Fogoros, S; Griffith, KA; Hu, YY; Liu, JR; Lucas, PC; Williams, J	1
Murphy, BA	1
Díaz, MA; González-Vicent, M; Lassaletta, A; Madero, L; Pérez-Martínez, A; Sevilla, J	1
Engelholm, SA; Gronlund, B; Horvath, G; Mäenpää, J; Ridderheim, M	1
Cromwell, LD; Fadul, CE; Kingman, LS; McDonnell, CE; Meyer, LP; Pipas, JM; Rhodes, CH; Rigas, JR	1
Blessing, JA; Lee, YC; Miller, DS; Munkarah, A; Schilder, J	1
Azodi, M; Kelly, M; Makkenchery, A; McAlpine, J; O'Malley, DM; Rutherford, T; Schwartz, P; Tangir, J	1
Farag, S; James, AG; Kraut, EH; Solove, RJ; Young, D	1
Beeler, JF; Haba, P; Rose, PG; Smrekar, M; Visser, C	1
Chang, MN; London, WB	1
Ditto, A; Fanfani, F; Luoni, C; Mariani, L; Oggionni, M; Pilotti, S; Scambia, G; Suardi, S; Zunino, F	1
Chen, MD; Fleming, GF; Horowitz, I; Mitchell, S	1
Adjei, AA; Ames, MM; Atherton, P; Erlichman, C; Gojo, I; Greer, J; Karp, JE; Kaufmann, SH; Kottke, TJ; Letendre, L; Litzow, MR; Loegering, DA; Reid, JM; Safgren, S; Sloan, JA; Svingen, PA	1
Armstrong, DK; Lane, S; Levin, J; Poulin, R; Spriggs, D	1
Belinson, JL; Michener, CM	1
Buller, R; Crawford, J; Garst, J; Lane, S	1
Cheung, NK; Danis, K; Kernan, NA; Kramer, K; Kushner, BH; Modak, S; Reich, LM	1
Hunold, A; Jürgens, H; Liebscher, C; Paulussen, M; Ranft, A; Weddeling, N	1
Adamson, PC; Blaney, SM; Bradfield, S; Franklin, J; Hawkins, DS; Krailo, M; Reaman, G; Whitlock, JA	1
Gosse, H; Huber, RM; Kleinschmidt, R; Mezger, J; Reck, M; Saal, JG; Steppert, C; Steppling, H; von Pawel, J	1
Birkmann, J; Fischer, L; Jahnke, K; Klasen, HA; Korfel, A; Martus, P; Thiel, E	1
Coleman, RL; Gibb, RK; Gossner, G; Herzog, TJ; Horowitz, NS; Mutch, DG; Powell, MA; Rader, JS	1
Davies, AM; Gandara, DR	1
Abratt, RP; Dane, G; Dharan, B; Gervais, R; Grotzinger, KM; Kaukel, E; Krzakowski, M; Ramlau, R; Ross, G; Shepherd, FA; von Pawel, J	1
Bădulescu, A; Bădulescu, F; Popescu, CF; Schenker, M; Stoica, Z	1
Economopoulos, T; Pectasides, D; Pectasides, M; Psyrri, A	1
duPont, NC; Monk, BJ	1
Gibb, R; Herzog, TJ; Mutch, DG; Powell, MA; Rader, JS	1
Harita, S; Hotta, K; Kiura, K; Kuyama, S; Nogami, N; Segawa, Y; Shibayama, T; Shinkai, T; Tabata, M; Tada, A; Takigawa, N; Tanimoto, M; Ueoka, H	1
Fangusaro, J; Finlay, J; Rook, J; Rosser, T	1
Grønlund, B	1
Aravantinos, G; Christodoulou, Ch; Malamos, NA; Rigatos, S; Skarlos, D; Stathopoulos, GP; Stathopoulos, J	1
Abraham, S; Booth, B; Brave, M; Dagher, R; Farrell, A; Gobburu, J; Jiang, X; Justice, R; Pazdur, R; Ramchandani, R; Sridhara, R	1
Canales Ugarte, S; Cassinello Espinosa, J	1
Ciuleanu, TE; Crofts, T; Cuceviá, B; Dane, GC; Juhasz, G; O'Brien, ME; Ross, GA; Shparyk, Y; Thatcher, N; Tsekov, H	1
Garst, J	1
Barter, J; Coleman, RL; Gordon, A; Herzog, TJ; Rackoff, W; Sun, S	1
Bernstein, R; Golan, A; Grisaru, D; Inbar, MJ; Levy, T; Menczer, J; Safra, T; Shpigel, S	1
Al Harbi, T; Al-Faris, N; Doyle, J; Gassas, A; Goia, C; Pappo, A	1
Berthold, F; Hero, B; Klingebiel, T; Längler, A; Simon, T	1
Nelson, R	1
Gajra, A; Garziano, S; Kirshner, J; Neuman, N; Perry, M; Ready, N; Shah, C	1
Cheng, S; Evans, WK; Shepherd, FA; Stys-Norman, D	1
Dakhil, S; Dy, GK; Geoffroy, FJ; Jett, JR; Krewer, KD; Krook, J; Kugler, J; Kutteh, L; Mailliard, J; Maurer, M; Rowland, K; Tazelaar, H; Wender, D	1
Berthold, F; Claviez, A; Frühwald, MC; Harnischmacher, U; Hero, B; Jorch, N; Längler, A; Simon, T	1
Brown, S; Carey, MS; Dancey, JE; Hirte, HW; Hotte, SJ; Oza, AM; Pond, GR; Tsao, MS; Welch, S	1
Alvarado, C; Billups, CA; Chintagumpala, M; Coppes, MJ; Daw, NC; Dome, JS; Freeman, BB; Grant, R; Hoffer, FA; Metzger, ML; Mullen, EA; Stewart, CF; Wu, J	1
Fels, C; Hau, P; Janssen, G; Liebeskind, AK; Peters, O; Sauerbrey, A; Suttorp, M; Wagner, S; Wolff, JE	1
Amant, F; Cadron, I; Leunen, K; Neven, P; Van Gorp, T; Vergote, I	1
Batchelor, T; Betensky, R; Hochberg, F; Voloschin, AD; Wen, PY	1
Abushahin, F; Grendys, EC; Lurain, JR; Rademaker, AW; Schink, JC; Singh, DK	1
Belau, A; Bogenrieder, T; Camara, O; Coumbos, A; Klare, P; Koensgen, D; Lichtenegger, W; Mustea, A; Oskay-Oezcelik, G; Sehouli, J; Sommer, H; Steck, T; Stengel, D	1
Govindan, R; Morgensztern, D; Perry, MC	1
Bamias, A; Giannopoulos, A; Gourgoulis, G; Mountzios, G; Papaiakovou, EE; Rodolakis, A; Vlahos, G; Voulgaris, Z	1
Abu-Ghazaleh, SZ; Argenta, PA; Bliss, RL; Boente, MP; Carson, LF; Chen, MD; Downs, LS; Geller, MA; Ghebre, R; Judson, PL; Nahhas, WA	1
Beldner, MA; Chaudhary, U; Garrett-Mayer, E; Green, MR; Kraft, AS; Meyer, ML; Montero, AJ; Sherman, CA	1
Alvarez, RD; Andrews, S; Bryant, C; Heilbrun, LK; Malone, J; Morris, R; Munkarah, A; Schimp, V; Smith, D	1
Chamorey, E; Creisson, A; Ferrero, JM; Hebert, C; Largillier, R; Lesbats, G; Mari, V; Novo, C; Valenza, B	1
Feun, L; Savaraj, N	1
Herzog, TJ; Wethington, SL; Wright, JD	1
Cairncross, G; Eisenhauer, E; Forsyth, P; Macdonald, D; Sawka, C; Stewart, D; Wainman, N	1
Dunton, CJ	1
Janik, JE; Saltz, L	1
Robert, F; Soong, SJ; Wheeler, RH	1
Ozols, RF	2
Bolis, G; Broom, C; Carmichael, J; Coleman, R; Davidson, N; Fields, SC; Gordon, A; Gore, M; Heron, JF; Hudson, I; Malfetano, J; Malmström, H; Scarabelli, C; Spanczynski, M; ten Bokkel Huinink, W	1
Balcerzak, SP; Gochnour, D; Kraut, EH; Staubus, A; Walker, MJ	1
Elbendary, A; Herzog, TJ; Mutch, DG; Rader, JS; Swisher, EM	1
Bell, B; Saylors, RL; Stewart, CF; Stine, KC; Vietti, TJ; Wall, DA; Zamboni, WC	1
Cass, I; Fields, AL; Goldberg, GL; Kuo, DY; Runowicz, CD	1
Abendstein, B; Klingler, PJ; Sevin, BU	1
Bolis, G; Bookman, MA; Fields, SZ; Gordon, A; Krebs, JB; Lissoni, A; Malmström, H	1
Baker, SD; Bowling, MK; Chen, TL; Donehower, RC; Gore, SD; Kaufmann, SH; Miller, CB; Rowinsky, EK; Sartorius, SE	1
Carmichael, J; Chrysson, NG; Clark, PI; Depierre, A; Fields, SZ; Gralla, R; Kleisbauer, JP; Krebs, JB; Lane, SR; Palmer, MC; Ross, G; Schiller, JH; Shepherd, FA; Stewart, DJ; von Pawel, J	1
Arbuck, S; Cokgor, I; Fields, S; Friedman, AH; Friedman, HS; Graden, D; Houghton, PJ; Kerby, T; McLendon, RE; Zilisch, JE	1
Bowman, LC; Gajjar, AJ; Heideman, RL; Houghton, PJ; Meyer, WH; Pappo, AS; Pratt, CB; Santana, VM; Stewart, CF; Tan, M; Zamboni, WC	1
Bookman, MA	1
Burger, PC; Friedman, HS; Heideman, RL; Horn, M; Kadota, RP; Kepner, JL; Kun, LE; Kuttesch, JF; Stewart, CF	1
Ghamande, SA; Piver, MS	1
Ames, MM; Frangoul, H; Holcenberg, JS; Krailo, MD; Mosher, RB; Reid, JM; Seibel, NL; Shaw, DW; Steinherz, PG; Whitlock, JA	1
Alvarez, RD; Blessing, JA; Hall, K; Hanjani, P; Markman, M; Waggoner, S	1
Aguilar-Cordova, E; Hasenburg, A; Kaplan, A; Kaufman, RH; Kieback, CC; Kieback, DG; Nyberg-Hoffman, C; Ramzy, I; Rojas-Martinez, A; Tong, XW	1
Blessing, JA; Kilgore, LC; Mannel, R; Miller, DS; Van Le, L	1
Bernath, AM; Buckner, JC; Burch, PA; Cascino, TL; Kugler, JW; Nair, S; Novotny, P; Pfeifle, DM; Scheithauer, BW; Tschetter, LK	1
Brown, JV; Dillman, RA; Drescher, CW; Karlan, BY; Micha, JP; Peters, WA; Rettenmaier, MA; Smith, MR	1
Gooley, T; Hawkins, D; Lindsley, K; Matthay, KK; Park, JR; Sanders, JE; Slattery, J; Villablanca, JG	1
Burkey, B; Forastiere, A; Langer, C; Leong, T; Murphy, BA	1
Bolis, G; Carmichael, J; Coleman, R; Davidson, N; Fields, SZ; Gordon, A; Gore, M; Héron, JF; Malfetano, J; Malmström, H; Ross, G; Scarabelli, C; Spaczynski, M; ten Bokkel Huinink, W; Vennin, P	1
Malik, IA	1
Fleagle, JT; Gordon, AN; Gore, ME; Guthrie, D; Lacave, AJ; Parkin, DE	1
Bernstein, ML; Harris, MB; Hayashi, R; Kepner, JL; Saylors, RL; Stine, KC; Sullivan, J; Vietti , TJ; Wall, DA	1
Aleman, AS; Bast, RC; Bevers, MW; Bodurka-Bevers, D; Burke, TW; Champlin, RE; Donato, ML; Freedman, RS; Gajewski, JL; Gershenson, DM; Ippoliti, CM; Levenback, CF; Wharton, JT; Wolf, JK	1
Cabanillas, F; Hagemeister, FB; McLaughlin, P; Palmer, JL; Preti, HA; Rodriguez, MA; Romaguera, JE; Samuels, BI; Younes, A	1
Berkowitz, RS; Campos, SM; Cook, S; Fuller, AF; Goodman, A; MacNeill, KM; Matulonis, UA; Penson, RT; Seiden, MV; Supko, JG	1
Anderson, JR; Breneman, JC; Crist, WM; Donaldson, SS; Grier, HE; Link, MP; Maurer, HM; Paidas, CN; Pappo, AS; Qualman, SJ; Raney, RB; Smith, LM; Teot, LA; Wiener, ES	1
Rodriguez, M; Rose, PG	1
Camlett, I; de Jonge, MJ; Gelderblom, H; Hennis, B; Loos, WJ; Mantel, MA; Sparreboom, A; van der Burg, ME; Verweij, J; Wilms, E	1
Beckman, RA; Calvert, H; Carmichael, J; Clarke-Pearson, D; Fields, SZ; Gore, M; Malfetano, J; Oza, A; Ross, G; Rustin, G	1
Feng, F; He, X; Shi, Y	1
Fietkau, R; Grüschow, K; Klautke, G	1
Anderson, JR; Barr, FG; Crist, WM; Donaldson, SS; Maurer, HM; Pappo, AS; Qualman, SJ; Raney, RB; Wiener, ES	1
Clark, JW; Eder, JP; Huang, KC; Kwiatkowski, D; Lynch, T; Ng, SW; Ryan, DP; Seiden, MV; Skarin, A; Supko, JG	1
Boothby, R; DeCesare, S; Fiorica, J; Grendys, E; Hoffman, M; Holloway, R; LaPolla, J; Ndubisi, B; Orr, J; Patel, J	1
Engelholm, SA; Gronlund, B; Hansen, HH; Høgdall, C	1
Hanjani, P; Nolte, S; Shahin, MS	1
Ames, MM; Krailo, MD; Mares, WL; Mosher, R; Reaman, GH; Reid, JM; Seibel, NL; Wells, RJ; Wiersma, SR	1
Crane, MM; Hunter, JE; Puls, LE	1
Bagaméri, A; Lehoczky, G; Lehoczky, O; Pulay, T	1
Hensley, ML	1

Reviews

41 review(s) available for topotecan and Local Neoplasm Recurrence

Article	Year
Management of recurrent ovarian cancer: when platinum-based regimens are not a therapeutic option. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2019, Volume: 29, Issue:9 Topics: Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Randomized Controlled Trials as Topic; Topotecan	2019
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms	2017
The prognostic and predictive role of pain before systemic chemotherapy in recurrent ovarian cancer: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1226 patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020, Volume: 28, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Pain; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Predictive Value of Tests; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Topotecan	2020
Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Current opinion in obstetrics & gynecology, 2014, Volume: 26, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mass Screening; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Topotecan; Uterine Cervical Neoplasms	2014
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2015, Volume: 19, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Gemcitabine; Health Care Costs; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tetrahydroisoquinolines; Topotecan; Trabectedin; Treatment Outcome; United Kingdom	2015
Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms	2015
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives. Japanese journal of clinical oncology, 2015, Volume: 45, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids	2015
Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients. Scientific reports, 2015, Oct-21, Volume: 5 Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Topotecan	2015
Optimal drugs for second-line treatment of patients with small-cell lung cancer. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:7 Topics: Anthracyclines; Antibodies, Monoclonal; Antineoplastic Agents; Humans; Immunotherapy; Ipilimumab; Lung Neoplasms; Neoplasm Recurrence, Local; Nivolumab; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan	2016
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials. Pediatric blood & cancer, 2017, Volume: 64, Issue:1 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Europe; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Prognosis; Salvage Therapy; Survival Rate; Temozolomide; Topotecan; Vincristine	2017
Chemotherapy for recurrent cervical cancer. Cancer treatment reviews, 2008, Volume: 34, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms	2008
New advances in the second-line treatment of small cell lung cancer. The oncologist, 2009, Volume: 14, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials as Topic; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Proto-Oncogene Proteins c-bcl-2; Quality of Life; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Treatment Outcome	2009
[Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment]. Brain and nerve = Shinkei kenkyu no shinpo, 2009, Volume: 61, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Methotrexate; Neoplasm Recurrence, Local; Rituximab; Salvage Therapy; Temozolomide; Topotecan	2009
Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix. Health technology assessment (Winchester, England), 2010, Volume: 14 Suppl 1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cost-Benefit Analysis; Cross-Linking Reagents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Quality of Life; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Topotecan; Treatment Outcome; United Kingdom; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine	2010
Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. Cancer treatment reviews, 2011, Volume: 37, Issue:3 Topics: Antineoplastic Agents; Cost-Benefit Analysis; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topotecan	2011
Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC cancer, 2010, Aug-17, Volume: 10 Topics: Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Topoisomerase Inhibitors; Topotecan	2010
Update on the role of topotecan in the treatment of recurrent ovarian cancer. The oncologist, 2002, Volume: 7 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Rate; Topotecan	2002
Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. The oncologist, 2002, Volume: 7 Suppl 5 Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	2002
Update on the treatment of cervical and uterine carcinoma: focus on topotecan. The oncologist, 2002, Volume: 7 Suppl 5 Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Endometrial Neoplasms; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Salvage Therapy; Topotecan; Uterine Cervical Neoplasms	2002
Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 40, Issue:3 Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Small Cell; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality of Life; Survival Analysis; Topotecan	2003
Clinical experience with topotecan in relapsed ovarian cancer. Gynecologic oncology, 2003, Volume: 90, Issue:3 Pt 2 Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Topotecan	2003
Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. The oncologist, 2004, Volume: 9, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Feasibility Studies; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Analysis; Topotecan	2004
Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature. Gynecologic oncology, 2004, Volume: 95, Issue:1 Topics: Aged; Antineoplastic Agents; Drug Administration Schedule; Endometrial Neoplasms; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan	2004
Topotecan in the treatment of recurrent small cell lung cancer: an update. The oncologist, 2004, Volume: 9 Suppl 6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan	2004
Emerging role of weekly topotecan in recurrent small cell lung cancer. The oncologist, 2004, Volume: 9 Suppl 6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Administration Schedule; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan	2004
Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:1 Topics: Camptothecin; Carcinoma, Squamous Cell; Clinical Trials as Topic; DNA Topoisomerases, Type I; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan	2005
Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. The oncologist, 2005, Volume: 10, Issue:9 Topics: Antineoplastic Agents; Bone Marrow; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hemoglobins; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Topotecan	2005
Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan? Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:8 Topics: Antineoplastic Agents; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Topotecan	2006
Chemotherapy in the management of cervical carcinoma. Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Humans; Neoplasm Recurrence, Local; Palliative Care; Topotecan; Uterine Cervical Neoplasms	2006
Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management. Danish medical bulletin, 2006, Volume: 53, Issue:3 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Denmark; Diagnostic Imaging; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Outcome	2006
Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer. Expert opinion on drug safety, 2007, Volume: 6, Issue:1 Topics: Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	2007
Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials, Phase III as Topic; Etoposide; Female; Humans; Infusions, Intravenous; Lomustine; Lung Neoplasms; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ontario; Practice Guidelines as Topic; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Topotecan	2007
Chemotherapy for recurrent cervical cancer. Gynecologic oncology, 2007, Volume: 107, Issue:1 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Neoplasm Recurrence, Local; Topotecan; Uterine Cervical Neoplasms	2007
Topoisomerase I inhibitors for the treatment of brain tumors. Expert review of anticancer therapy, 2008, Volume: 8, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local; Survival Analysis; Topoisomerase I Inhibitors; Topotecan	2008
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. Expert review of anticancer therapy, 2008, Volume: 8, Issue:5 Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	2008
New options for the treatment of advanced ovarian cancer. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Remission Induction; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	1997
Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor? Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Bone Marrow; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	1997
Future directions in the chemotherapy of ovarian cancer. Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15 Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine	1997
Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. The oncologist, 1999, Volume: 4, Issue:2 Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Recurrence; Salvage Therapy; Time Factors; Topotecan	1999
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infant; Male; Melphalan; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Rhabdomyosarcoma; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Topotecan; Treatment Outcome; Vincristine	2001
Epithelial ovarian cancer. Current treatment options in oncology, 2002, Volume: 3, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine	2002

Trials

142 trial(s) available for topotecan and Local Neoplasm Recurrence

Article	Year
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial. The Lancet. Oncology, 2022, Volume: 23, Issue:11 Topics: Convection; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Topotecan	2022
Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ). Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Leukopenia; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Topotecan	2023
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies. The oncologist, 2023, 07-05, Volume: 28, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Genital Neoplasms, Female; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Topotecan	2023
Phase II study of Pediatric blood & cancer, 2023, Volume: 70, Issue:11 Topics: 3-Iodobenzylguanidine; Adolescent; Busulfan; Child; Child, Preschool; Chronic Disease; Humans; Melphalan; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan; Young Adult	2023
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 03-01, Volume: 26, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Safety; Polyethylene Glycols; Survival Rate; Topotecan; Treatment Outcome	2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 11-10, Volume: 38, Issue:32 Topics: Adult; Aged; Benzimidazoles; Cystadenocarcinoma, Serous; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Protein Kinase Inhibitors; Topotecan; Young Adult	2020
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Oct-10, Volume: 35, Issue:29 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome	2017
Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018, Volume: 20, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cost-Benefit Analysis; Etoposide; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Quality-Adjusted Life Years; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2018
Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. Cancer treatment and research communications, 2018, Volume: 14 Topics: Adenocarcinoma; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Recurrence; Topotecan	2018
Discrepancies of assessments in a RECIST 1.1 phase II clinical trial - association between adjudication rate and variability in images and tumors selection. Cancer imaging : the official publication of the International Cancer Imaging Society, 2018, Dec-11, Volume: 18, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Observer Variation; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Risk Factors; Small Cell Lung Carcinoma; Taxoids; Topotecan; Tumor Burden	2018
Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study. Minerva ginecologica, 2019, Volume: 71, Issue:3 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy; Topotecan	2019
Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:3 Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Israel; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Topotecan	2013
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecologic oncology, 2013, Volume: 130, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Topotecan; Uterine Cervical Neoplasms; Young Adult	2013
A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Palliative Care; Small Cell Lung Carcinoma; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan	2013
Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma. Pediatric blood & cancer, 2013, Volume: 60, Issue:10 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Topotecan; Transplantation, Autologous	2013
Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Recurrence; Temozolomide; Topotecan; Young Adult	2014
Improved survival with bevacizumab in advanced cervical cancer. The New England journal of medicine, 2014, Feb-20, Volume: 370, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Analysis; Topotecan; Uterine Cervical Neoplasms	2014
Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Endometrial Neoplasms; Everolimus; Female; Humans; Immunosuppressive Agents; Middle Aged; Neoplasm Recurrence, Local; Sirolimus; Topoisomerase I Inhibitors; Topotecan; TOR Serine-Threonine Kinases	2014
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, May-01, Volume: 32, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Topotecan	2014
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult	2014
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Gynecologic oncology, 2014, Volume: 135, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Recombinant Fusion Proteins; Topoisomerase I Inhibitors; Topotecan	2014
Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG). Pediatric blood & cancer, 2015, Volume: 62, Issue:4 Topics: Adolescent; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infant; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Wilms Tumor	2015
A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma; Cell Cycle Proteins; Disease Progression; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Polyethylene Glycols; Recombinant Proteins; Ribonucleotide Reductases; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms	2015
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). The Lancet. Oncology, 2015, Volume: 16, Issue:3 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Quality of Life; Risk Factors; Surveys and Questionnaires; Time Factors; Topotecan; Treatment Outcome; United States; Uterine Cervical Neoplasms	2015
Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-10, Volume: 33, Issue:32 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Polyethylene Glycols; Prognosis; Risk Factors; Topotecan; Treatment Outcome	2015
HIGH-DOSE 131I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS. Radiation protection dosimetry, 2017, Apr-15, Volume: 173, Issue:4 Topics: 3-Iodobenzylguanidine; Adult; Caregivers; Child; Female; France; Humans; Iodine Radioisotopes; Male; Neoplasm Recurrence, Local; Neuroblastoma; Radiation Exposure; Radiometry; Topoisomerase I Inhibitors; Topotecan	2017
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. The Lancet. Oncology, 2016, Volume: 17, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2016
A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PloS one, 2016, Volume: 11, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Caprylates; Cell Line, Tumor; Female; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Sulfides; Topoisomerase I Inhibitors; Topotecan	2016
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality of Life; Topotecan	2016
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. Oncotarget, 2017, Apr-04, Volume: 8, Issue:14 Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Sirolimus; Topotecan; Young Adult	2017
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecologic oncology, 2017, Volume: 144, Issue:1 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Hypertension; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Selection; Platinum Compounds; Polyethylene Glycols; Topotecan	2017
Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium. Gynecologic oncology, 2008, Volume: 110, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Quality of Life; Topotecan	2008
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-01, Volume: 26, Issue:19 Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Deoxycytidine; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Proportional Hazards Models; Quality of Life; Survival Rate; Topotecan; Treatment Outcome	2008
Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. Gynecologic oncology, 2008, Volume: 111, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Topotecan	2008
Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecologic oncology, 2008, Volume: 111, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan; Vinblastine; Vinorelbine	2008
Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer. Medical oncology (Northwood, London, England), 2009, Volume: 26, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Topotecan; Uterine Cervical Neoplasms	2009
A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Young Adult	2009
A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma. Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan; Uterine Cervical Neoplasms	2010
Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO). Thrombosis research, 2009, Volume: 124, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Venous Thromboembolism	2009
Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekolog Gynecologic oncology, 2009, Volume: 114, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Rate; Topotecan	2009
Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study. Gynecologic oncology, 2009, Volume: 114, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Epithelial Cells; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Survival Rate; Topotecan	2009
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-01, Volume: 27, Issue:28 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Quality of Life; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine; Young Adult	2009
Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system. Pediatric blood & cancer, 2010, Volume: 54, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Neoplasm Recurrence, Local; Prognosis; Thiotepa; Topotecan; Young Adult	2010
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Spinal Cord Neoplasms; Tamoxifen; Topotecan; Young Adult	2010
A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecologic oncology, 2010, Volume: 117, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Sirolimus; Topotecan	2010
Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:15 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Humans; Infant; Neoplasm Recurrence, Local; Neoplasms; Temozolomide; Topotecan; Treatment Outcome; Tumor Protein, Translationally-Controlled 1; Young Adult	2010
Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Drug Resistance, Neoplasm; Female; Gossypol; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Treatment Outcome	2010
Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecologic oncology, 2010, Volume: 119, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine	2010
A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:3 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Cohort Studies; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Salvage Therapy; Survival Rate; Tissue Distribution; Topoisomerase I Inhibitors; Topotecan	2011
An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer. Gynecologic oncology, 2011, Volume: 120, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	2011
A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecologic oncology, 2011, Volume: 120, Issue:3 Topics: Adult; Aged; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Topoisomerase I Inhibitors; Topotecan	2011
Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Topotecan	2012
A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer. Clinical lung cancer, 2011, Volume: 12, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan	2011
Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer. Oncology, 2011, Volume: 80, Issue:5-6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Topoisomerase I Inhibitors; Topotecan; Treatment Failure; Uterine Cervical Neoplasms	2011
Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962). Pediatric blood & cancer, 2012, Volume: 58, Issue:3 Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Spinal; Leukemia; Male; Meningeal Neoplasms; Neoplasm Recurrence, Local; Survival Analysis; Topoisomerase I Inhibitors; Topotecan; Young Adult	2012
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecologic oncology, 2011, Volume: 123, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Topotecan	2011
Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study. Clinical lung cancer, 2013, Volume: 14, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Topotecan	2013
Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies. American journal of clinical oncology, 2002, Volume: 25, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm, Residual; Neutropenia; Recombinant Proteins; Survival Analysis; Topotecan; Vinblastine; Vinorelbine	2002
A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:11 Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Probability; Survival Analysis; Topotecan; Treatment Failure; Treatment Outcome	2002
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:6 Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Infusions, Intravenous; Leukemia, Myeloid; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Topotecan; Treatment Outcome	2002
A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecologic oncology, 2002, Volume: 87, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Topotecan	2002
Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecologic oncology, 2003, Volume: 88, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Epithelial Cells; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Recombinant Proteins; Topotecan	2003
Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jun-01, Volume: 21, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Survival Rate; Topotecan; United States	2003
A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan	2003
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. Cancer, 2003, Oct-15, Volume: 98, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	2003
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Disease Progression; Drug Administration Schedule; Female; Humans; Incidence; Infusions, Intravenous; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Sensitivity and Specificity; Survival Analysis; Topotecan	2004
Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? British journal of cancer, 2004, Jan-26, Volume: 90, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carcinoma; Cisplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Reference Values; Topotecan; Treatment Outcome; World Health Organization	2004
Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors. Pediatric blood & cancer, 2004, Volume: 42, Issue:1 Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Salvage Therapy; Topotecan	2004
Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecologic oncology, 2004, Volume: 92, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Uterine Cervical Neoplasms	2004
Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum. Onkologie, 2004, Volume: 27, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure	2004
Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta paediatrica (Oslo, Norway : 1992). Supplement, 2004, Volume: 93, Issue:445 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Dacarbazine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Palliative Care; Temozolomide; Topotecan; Treatment Outcome	2004
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecologic oncology, 2004, Volume: 95, Issue:1 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Survival Rate; Topotecan	2004
Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecologic oncology, 2004, Volume: 95, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Epithelial Cells; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2004
High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. Journal of neuro-oncology, 2005, Volume: 71, Issue:1 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cerebellar Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Neuroectodermal Tumors, Primitive; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Supratentorial Neoplasms; Thiotepa; Topotecan; Transplantation, Autologous; Treatment Outcome	2005
Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study. Cancer, 2005, Apr-01, Volume: 103, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Drug Administration Schedule; Etoposide; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Taxoids; Topotecan	2005
A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. Journal of neuro-oncology, 2005, Volume: 71, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Filgrastim; Glioblastoma; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Recombinant Proteins; Thrombocytopenia; Topotecan; Treatment Outcome	2005
Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecologic oncology, 2005, Volume: 98, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinosarcoma; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Recurrence, Local; Topotecan; Uterine Neoplasms	2005
A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. Gynecologic oncology, 2005, Volume: 99, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2005
A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study. Gynecologic oncology, 2006, Volume: 100, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2006
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-15, Volume: 11, Issue:18 Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carboplatin; Cell Cycle Proteins; Combined Modality Therapy; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; HL-60 Cells; Humans; Immunoblotting; Infusions, Intravenous; Leukemia; Male; Middle Aged; Neoplasm Recurrence, Local; Proliferating Cell Nuclear Antigen; Topotecan; Treatment Outcome	2005
Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system. Bone marrow transplantation, 2006, Volume: 37, Issue:3 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Male; Neoplasm Recurrence, Local; Neuroblastoma; Thiotepa; Topotecan; Treatment Failure	2006
Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatric blood & cancer, 2006, Volume: 47, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Sarcoma, Ewing; Survival Rate; Topotecan; Treatment Outcome	2006
Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study. Pediatric blood & cancer, 2006, Volume: 47, Issue:6 Topics: Adolescent; Adult; Astrocytoma; Child; Child, Preschool; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Neuroectodermal Tumors, Primitive; Neutropenia; Recurrence; Sarcoma; Survival Rate; Thrombocytopenia; Time Factors; Topotecan; Treatment Outcome	2006
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. The European respiratory journal, 2006, Volume: 27, Issue:6 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Neutrophils; Organoplatinum Compounds; Platelet Count; Retreatment; Survival Rate; Topotecan; Treatment Outcome	2006
Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Salvage Therapy; Survival Analysis; Topotecan	2006
Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Topotecan	2006
Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecologic oncology, 2006, Volume: 103, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Epithelial Cells; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan	2006
A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 53, Issue:2 Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers; Carcinoma, Small Cell; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Topotecan; Treatment Outcome	2006
Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Remission Induction; Thrombocytopenia; Topotecan; Treatment Outcome	2007
Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Topotecan; Uterine Cervical Neoplasms	2006
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Dec-01, Volume: 24, Issue:34 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Quality of Life; Survival Rate; Topotecan	2006
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. The oncologist, 2007, Volume: 12, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CA-125 Antigen; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Retrospective Studies; Topotecan; Treatment Outcome	2007
Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecologic oncology, 2007, Volume: 105, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Prospective Studies; Topotecan	2007
Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. Journal of pediatric hematology/oncology, 2007, Volume: 29, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan; Treatment Outcome	2007
A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2007, Volume: 57, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Survival Analysis; Thrombocytopenia; Time Factors; Topotecan; Vomiting	2007
Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Topotecan	2006
Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. Journal of cancer research and clinical oncology, 2007, Volume: 133, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Male; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan; Treatment Outcome	2007
UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecologic oncology, 2007, Volume: 106, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Staurosporine; Topotecan	2007
Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jul-20, Volume: 25, Issue:21 Topics: Area Under Curve; Child; Child, Preschool; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Kidney Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Risk Assessment; Survival Analysis; Topotecan; Treatment Outcome; Wilms Tumor	2007
Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. Journal of neuro-oncology, 2008, Volume: 86, Issue:2 Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Child; Child, Preschool; Choroid Plexus Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Eruptions; Glioblastoma; Hematologic Diseases; Humans; Neoplasm Recurrence, Local; Polyethylene Glycols; Recurrence; Retrospective Studies; Stomatitis; Topotecan; Treatment Outcome	2008
Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. Journal of neuro-oncology, 2008, Volume: 86, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Topotecan; Treatment Outcome	2008
Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prospective Studies; Topotecan	2008
A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Docetaxel; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Recombinant Proteins; Taxoids; Topotecan; Treatment Failure	2008
A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer, 2008, Jan-15, Volume: 112, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Thalidomide; Topotecan	2008
Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC cancer, 2007, Dec-20, Volume: 7 Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Topotecan; Vinblastine; Vinorelbine	2007
Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers. Gynecologic oncology, 2008, Volume: 109, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Prospective Studies; Survival Rate; Topotecan	2008
Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioblastoma; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Topotecan; Treatment Outcome	1996
A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent. American journal of clinical oncology, 1997, Volume: 20, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Quality of Life; Remission Induction; Survival Analysis; Topotecan	1997
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Survival Analysis; Topotecan	1997
Phase II trial of topotecan in malignant melanoma. Cancer investigation, 1997, Volume: 15, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Topotecan	1997
Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecologic oncology, 1997, Volume: 66, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Analysis; Topotecan; Treatment Outcome	1997
Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Salvage Therapy; Topotecan	1998
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Treatment Outcome	1998
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:12 Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Bone Marrow; DNA Topoisomerases, Type I; Female; Humans; Leukemia; Male; Middle Aged; Mucous Membrane; Neoplasm Recurrence, Local; Topotecan; Treatment Outcome	1996
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Topotecan; Vincristine	1999
Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer, 1999, Mar-01, Volume: 85, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Topotecan; Treatment Outcome	1999
Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study. Journal of neuro-oncology, 1999, Volume: 43, Issue:1 Topics: Adult; Antineoplastic Agents; Central Nervous System Neoplasms; Child; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Tomography, X-Ray Computed; Topotecan	1999
Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study. Journal of surgical oncology, 1999, Volume: 72, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Salvage Therapy; Topotecan	1999
Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:12 Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Neoplasm Recurrence, Local; Topotecan	1999
Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study. Gynecologic oncology, 2000, Volume: 77, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Palliative Care; Thrombocytopenia; Topotecan; Treatment Outcome	2000
Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer gene therapy, 2000, Volume: 7, Issue:6 Topics: Acyclovir; Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenoviridae; Adult; Aged; Antiviral Agents; Combined Modality Therapy; Cystadenocarcinoma, Papillary; DNA; Enzyme Inhibitors; Female; Follow-Up Studies; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polymerase Chain Reaction; Thymidine Kinase; Topotecan	2000
Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. American journal of clinical oncology, 2000, Volume: 23, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Cohort Studies; Disease Progression; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Leiomyosarcoma; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Remission Induction; Thrombocytopenia; Topotecan; Uterine Neoplasms	2000
A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas. Investigational new drugs, 2000, Volume: 18, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Topotecan	2000
A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gynecologic oncology, 2000, Volume: 79, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Epithelium; Fallopian Tube Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Klebsiella Infections; Klebsiella pneumoniae; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Sleep Stages; Topotecan	2000
Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. Medical and pediatric oncology, 2000, Volume: 35, Issue:6 Topics: Antineoplastic Agents; Child; Child, Preschool; Combined Modality Therapy; Glioma; Hematopoietic Stem Cell Transplantation; Humans; Infant; Neoplasm Recurrence, Local; Neuroblastoma; Topotecan	2000
Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393). American journal of clinical oncology, 2001, Volume: 24, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Topotecan	2001
Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-01, Volume: 19, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cross-Over Studies; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Europe; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Survival Rate; Topotecan; United States	2001
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jul-15, Volume: 19, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Doxorubicin; Female; Humans; Liposomes; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Sickness Impact Profile; Survival Analysis; Topotecan	2001
Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Aug-01, Volume: 19, Issue:15 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Infant; Infusions, Intravenous; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma, Ewing; Topotecan	2001
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecologic oncology, 2001, Volume: 82, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Survival Rate; Topotecan	2001
Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:7 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutrophils; Paclitaxel; Topotecan; Treatment Outcome	2001
A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer, 2001, Sep-01, Volume: 92, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Statistics, Nonparametric; Survival Rate; Topotecan	2001
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer. British journal of cancer, 2001, Oct-19, Volume: 85, Issue:8 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Glycerol; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	2001
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Tomography, X-Ray Computed; Topotecan	2002
[Clinical study of topotecan in the treatment of small cell lung cancer and recurrent ovarian cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2001, Volume: 23, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Female; Humans; Leukopoiesis; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan; Treatment Outcome	2001
Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Tomography, X-Ray Computed; Topotecan; Treatment Outcome	2002
A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:3 Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; DNA Primers; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Doxorubicin; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Safety; Topotecan; Treatment Outcome	2002
Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecologic oncology, 2002, Volume: 85, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Topotecan; Uterine Cervical Neoplasms	2002
Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer. Gynecologic oncology, 2002, Volume: 85, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	2002
Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:2 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Rhabdomyosarcoma; Salvage Therapy; Topotecan; Treatment Outcome	2002
Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma. Medical oncology (Northwood, London, England), 2002, Volume: 19, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prospective Studies; Time Factors; Topotecan; Treatment Outcome	2002
[Early results of topotecan therapy in patients with recurrent ovarian cancer]. Orvosi hetilap, 2002, Apr-21, Volume: 143, Issue:16 Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prospective Studies; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2002

Other Studies

111 other study(ies) available for topotecan and Local Neoplasm Recurrence

Article	Year
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study. American journal of obstetrics and gynecology, 2023, Volume: 228, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cervix Uteri; Cisplatin; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Registries; Retrospective Studies; Topotecan; Uterine Cervical Neoplasms	2023
Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series. Scientific reports, 2023, 11-07, Volume: 13, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Child; Chronic Disease; Cyclophosphamide; Humans; Mice; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Neuroblastoma; Proto-Oncogene Proteins c-bcl-2; Topotecan	2023
Novel treatment of refractory / recurrent pulmonary hepatoblastoma. Pediatrics international : official journal of the Japan Pediatric Society, 2020, Volume: 62, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Female; Hepatoblastoma; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Oxaliplatin; Radiofrequency Ablation; Retrospective Studies; Survival Rate; Topotecan; Treatment Outcome; Vincristine	2020
Leptomeningeal Relapse of Embryonal Rhabdomyosarcoma after 15 years. Irish medical journal, 2020, 12-16, Volume: 112, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child, Preschool; Cyclophosphamide; Ear Neoplasms; Humans; Male; Meningeal Neoplasms; Neoplasm Recurrence, Local; Radiotherapy Dosage; Rare Diseases; Rhabdomyosarcoma, Embryonal; Time Factors; Topotecan; Treatment Outcome; Young Adult	2020
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. Lung cancer (Amsterdam, Netherlands), 2020, Volume: 146 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Topotecan	2020
Effectiveness of intravitreal chemotherapy-assisted endoresection in monocular patients with group D retinoblastoma. BMC cancer, 2020, Aug-26, Volume: 20, Issue:1 Topics: Chemotherapy, Adjuvant; Child; Child, Preschool; Follow-Up Studies; Humans; Infant; Intravitreal Injections; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Seeding; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Salvage Therapy; Topotecan; Treatment Outcome; Visual Acuity; Vitrectomy; Vitreous Body	2020
Carboplatin plus etoposide or topotecan for small-cell lung cancer. The Lancet. Oncology, 2020, Volume: 21, Issue:9 Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan	2020
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2020, Volume: 30, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan	2020
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer. The Lancet. Oncology, 2020, Volume: 21, Issue:12 Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma; Topotecan	2020
Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer - Authors' reply. The Lancet. Oncology, 2020, Volume: 21, Issue:12 Topics: Carboplatin; Etoposide; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topotecan	2020
Bulletin du cancer, 2017, Volume: 104 Suppl 1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Topotecan	2017
Successful conservative treatment of massive choroidal relapse in 2 retinoblastoma patients monitored by ultrasound biomicroscopy and/or spectral domain optic coherence tomography. Ophthalmic genetics, 2018, Volume: 39, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Choroid Neoplasms; Conservative Treatment; Fatal Outcome; Female; Fluorescein Angiography; Humans; Infant; Infusions, Intra-Arterial; Magnetic Resonance Imaging; Melphalan; Microscopy, Acoustic; Neoplasm Recurrence, Local; Retinal Neoplasms; Retinoblastoma; Tomography, Optical Coherence; Topotecan	2018
ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy. Medicine, 2017, Volume: 96, Issue:51 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma; Cisplatin; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pelvic Neoplasms; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms	2017
The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer. Medicine, 2018, Volume: 97, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms	2018
Feasibility and results of an intraarterial chemotherapy program for the conservative treatment of retinoblastoma in Argentina. Pediatric blood & cancer, 2018, Volume: 65, Issue:8 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Argentina; Carboplatin; Child; Child, Preschool; Conservative Treatment; Disease-Free Survival; Feasibility Studies; Female; Humans; Infusions, Intra-Arterial; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Ophthalmic Artery; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Topotecan; Young Adult	2018
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer. European journal of gynaecological oncology, 2017, Volume: 38, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan	2017
Treatment of platinum refractory or resistant ovarian cancer. The Lancet. Oncology, 2018, Volume: 19, Issue:9 Topics: Double-Blind Method; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Sorafenib; Topotecan	2018
Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041). Gynecologic oncology, 2019, Volume: 152, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Polyethylene Glycols; Topotecan	2019
The clinical conundrum of managing relapsed small cell lung cancer. Cancer, 2019, 04-01, Volume: 125, Issue:7 Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Carboplatin; Clinical Decision-Making; Disease Progression; Etoposide; Humans; Immunoconjugates; Irinotecan; Liver Neoplasms; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Nivolumab; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy; Small Cell Lung Carcinoma; Temozolomide; Thiourea; Topotecan	2019
Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer. Anticancer research, 2019, Volume: 39, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Republic of Korea; Topotecan	2019
Dosimetry-based high-activity therapy with European journal of nuclear medicine and molecular imaging, 2019, Volume: 46, Issue:7 Topics: 3-Iodobenzylguanidine; Adolescent; Chemoradiotherapy; Child; Child, Preschool; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Male; Neoplasm Recurrence, Local; Neuroblastoma; Progression-Free Survival; Radiometry; Recurrence; Remission Induction; Retrospective Studies; Risk; Topotecan; Treatment Outcome; Young Adult	2019
Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base. Gynecologic oncology, 2019, Volume: 154, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Young Adult	2019
Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols. Acta pharmaceutica (Zagreb, Croatia), 2019, Mar-01, Volume: 69, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Topotecan; Treatment Outcome; Young Adult	2019
Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Topotecan	2013
A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors. Pediatric hematology and oncology, 2013, Volume: 30, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Sarcoma, Ewing; Topotecan; Vincristine	2013
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Cyclophosphamide; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Topotecan	2013
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan	2013
Synergistic effect of combination topotecan and chronomodulated radiation therapy on xenografted human nasopharyngeal carcinoma. International journal of radiation oncology, biology, physics, 2013, Oct-01, Volume: 87, Issue:2 Topics: Animals; Carcinoma; Cell Hypoxia; Chronotherapy; Combined Modality Therapy; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Radiation; Histones; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Nitroimidazoles; Phosphorylation; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous	2013
Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014, Volume: 20, Issue:3 Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Cerebellar Neoplasms; Ependymoma; Humans; Injections, Spinal; Male; Medulloblastoma; Meningeal Neoplasms; Neoplasm Recurrence, Local; Pilot Projects; Topotecan; Treatment Outcome; Young Adult	2014
Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin. Annals of surgical oncology, 2014, Volume: 21, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cystadenocarcinoma, Serous; Etoposide; Female; Floxuridine; Follow-Up Studies; Heterozygote; Humans; Injections, Intraperitoneal; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Survival Rate; Topotecan	2014
Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. Gynecologic oncology, 2014, Volume: 133, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Chemotherapy-Induced Febrile Neutropenia; Cost-Benefit Analysis; Docetaxel; Drug Costs; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Taxoids; Topotecan	2014
Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:13 Topics: Aged; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Small Cell Lung Carcinoma; Survival Analysis; Topoisomerase I Inhibitors; Topotecan	2014
Proposed strategy for the use of high-dose chemotherapy with stem cell rescue and intrathecal topotecan without whole-brain irradiation for infantile classic medulloblastoma. Pediatric blood & cancer, 2014, Volume: 61, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Female; Humans; Infant; Injections, Spinal; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Prognosis; Stem Cell Transplantation; Topotecan; Transplantation, Autologous	2014
The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience. Taiwanese journal of obstetrics & gynecology, 2015, Volume: 54, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Taiwan; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2015
Clinical observational study of conformal radiotherapy combined with topotecan chemotherapy in patients with platinum-resistant recurrent ovarian cancer. Genetics and molecular research : GMR, 2015, Apr-22, Volume: 14, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Radiotherapy, Conformal; Retrospective Studies; Topotecan; Treatment Outcome	2015
Rescue intra-arterial chemotherapy following retinoblastoma recurrence after initial intra-arterial chemotherapy. Journal francais d'ophtalmologie, 2015, Volume: 38, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child, Preschool; Eye Enucleation; Female; Follow-Up Studies; Humans; Infant; Infusions, Intra-Arterial; Male; Melphalan; Neoplasm Recurrence, Local; Retinal Neoplasms; Retinoblastoma; Retinoscopy; Retreatment; Salvage Therapy; Topotecan; Treatment Failure; Treatment Outcome	2015
Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. Clinical lung cancer, 2015, Volume: 16, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum Compounds; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Topotecan; Treatment Outcome	2015
Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:3 Topics: Aged; Aged, 80 and over; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Topoisomerase I Inhibitors; Topotecan	2015
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. Gynecologic oncology, 2015, Volume: 139, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Radiography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate; Taxoids; Topotecan; Young Adult	2015
Topotecan plus cyclophosphamide in adults with relapsed or refractory pediatric-type sarcoma: a retrospective analysis from the German Sarcoma Medical Oncology Group (AIO). Investigational new drugs, 2015, Volume: 33, Issue:5 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Sarcoma; Survival Analysis; Topotecan; Young Adult	2015
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. Gynecologic oncology, 2015, Volume: 139, Issue:2 Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan	2015
Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer. Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Topotecan	2016
Analysis of two topotecan treatment schedules in patients with recurrent ovarian cancer. Journal of chemotherapy (Florence, Italy), 2016, Volume: 28, Issue:2 Topics: Adult; Aged; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan	2016
Secondary and tertiary intra-arterial chemotherapy for massive persistent or recurrent subretinal retinoblastoma seeds following previous chemotherapy exposure: long-term tumor control and globe salvage in 30 eyes. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 2016, Volume: 20, Issue:4 Topics: Antineoplastic Agents; Carboplatin; Child, Preschool; Female; Humans; Infant; Male; Melphalan; Neoplasm Recurrence, Local; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Topotecan	2016
Intra-arterial Chemotherapy for Adult Onset Retinoblastoma in a 32-Year-Old Man. Journal of pediatric ophthalmology and strabismus, 2016, Jul-30, Volume: 53 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined Modality Therapy; Humans; Infusions, Intra-Arterial; Male; Melphalan; Neoplasm Recurrence, Local; Neoplasm Seeding; Retinal Neoplasms; Retinoblastoma; Topotecan; Ultrasonography; Visual Acuity; Vitreous Body	2016
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix. Gynecologic oncology, 2017, Volume: 144, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Young Adult	2017
Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. Gynecologic oncology, 2008, Volume: 110, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Topotecan	2008
Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma. Medical oncology (Northwood, London, England), 2009, Volume: 26, Issue:1 Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Neoplasm Recurrence, Local; Rhabdomyosarcoma; Topotecan; Treatment Outcome; Vincristine	2009
Trilateral retinoblastoma with pituitary-hypothalamic dysfunction. Ophthalmic genetics, 2008, Volume: 29, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Etoposide; Fatal Outcome; Female; Gestational Age; Humans; Hypothalamic Diseases; Infant; Infusions, Parenteral; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Pituitary Neoplasms; Retinal Neoplasms; Retinoblastoma; Retinoblastoma Protein; Tomography, X-Ray Computed; Topotecan; Vincristine	2008
Extrapulmonary small cell carcinoma: involvement of the brain without evidence of extracranial malignancy by serial PET/CT scans. World journal of surgical oncology, 2008, Sep-25, Volume: 6 Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Combined Modality Therapy; Craniotomy; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Topotecan	2008
Symptom assessment in relapsed small cell lung cancer: cross-validation of the patient symptom assessment in lung cancer instrument. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Palliative Care; Randomized Controlled Trials as Topic; Self-Assessment; Severity of Illness Index; Sickness Impact Profile; Small Cell Lung Carcinoma; Surveys and Questionnaires; Topotecan	2008
Three-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Topotecan; Treatment Outcome	2009
[Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Topotecan	2009
Chemotherapy: Topotecan or treosulfan--that is the question. Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10 Topics: Antineoplastic Agents; Busulfan; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance; Drug Therapy; Female; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Survival Analysis; Time Factors; Topotecan	2009
Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response. Pediatric blood & cancer, 2010, Volume: 54, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Pilot Projects; Prognosis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Salvage Therapy; Survival Rate; Topotecan; Treatment Outcome	2010
Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases. The Journal of reproductive medicine, 2009, Volume: 54, Issue:9 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fatigue; Female; Humans; Immunosuppressive Agents; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Thalidomide; Topotecan	2009
Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience. The journal of obstetrics and gynaecology research, 2010, Volume: 36, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Epithelium; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Topotecan	2010
Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer. Archives of gynecology and obstetrics, 2011, Volume: 283, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Survival Rate; Topoisomerase I Inhibitors; Topotecan	2011
The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Synergism; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiation-Sensitizing Agents; Salvage Therapy; Topotecan; Uterine Cervical Neoplasms	2010
[Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report]. Pneumonologia i alergologia polska, 2010, Volume: 78, Issue:3 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Poland; Proportional Hazards Models; Recurrence; Survival Analysis; Topotecan; Treatment Outcome	2010
Sequence-dependent hematologic side effects of topotecan and cisplatin in persistent or recurrent cervical cancer. Gynecologic oncology, 2010, Volume: 119, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Topotecan; Uterine Cervical Neoplasms	2010
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:11 Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan	2010
Multifaceted chemotherapy for trilateral retinoblastoma. Archives of ophthalmology (Chicago, Ill. : 1960), 2011, Volume: 129, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cyclosporine; Cytarabine; Etoposide; Fatal Outcome; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Pineal Gland; Retinal Neoplasms; Retinoblastoma; Tomography, X-Ray Computed; Topotecan; Vincristine	2011
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma. Gynecologic oncology, 2011, Volume: 122, Issue:1 Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome	2011
Long-term topotecan therapy in recurrent or persistent ovarian cancer. European journal of gynaecological oncology, 2011, Volume: 32, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Disease Progression; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome	2011
Long-term survival of a child with refractory anaplastic large cell lymphoma following therapy with an antisense oligonucleotide, topotecan, and vinblastine. Hematological oncology, 2015, Volume: 33, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Down-Regulation; Drug Resistance, Neoplasm; Humans; Lymphoma, Large-Cell, Anaplastic; Male; Neoplasm Recurrence, Local; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Survivors; Topotecan; Vinblastine	2015
Weekly topotecan for recurrent small cell lung cancer - a retrospective Anatolian Medical Oncology Group study. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:6 Topics: Adult; Aged; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Topotecan; Treatment Outcome	2012
Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatric blood & cancer, 2013, Volume: 60, Issue:5 Topics: Administration, Intravenous; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Injections, Intra-Arterial; Injections, Intraocular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Ophthalmic Artery; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Salvage Therapy; Topotecan; Treatment Outcome; Vincristine; Young Adult	2013
Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution. Journal of pediatric hematology/oncology, 2013, Volume: 35, Issue:5 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Male; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Sarcoma, Ewing; Topotecan; Treatment Outcome; Young Adult	2013
[Chemotherapy for recurrent ovarian cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Topotecan	2012
[Treatment of recurrent ovarian cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 4 Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Reoperation; Topotecan	2012
Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Feb-15, Volume: 19, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Female; Humans; Liposomes; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Topotecan; Treatment Outcome	2013
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer. American journal of clinical oncology, 2015, Volume: 38, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cohort Studies; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Small Cell Lung Carcinoma; Time Factors; Topotecan; Treatment Outcome	2015
The role of topotecan as second-line therapy in patients with recurrent ovarian cancer. European journal of gynaecological oncology, 2002, Volume: 23, Issue:4 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Endometrioid; Cystadenocarcinoma, Papillary; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Medical Records; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Topotecan	2002
A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum. The journal of obstetrics and gynaecology research, 2003, Volume: 29, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Rate; Thrombocytopenia; Topotecan; Treatment Failure	2003
Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. Journal of pediatric hematology/oncology, 2003, Volume: 25, Issue:8 Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Male; Neoplasm Recurrence, Local; Neuroblastoma; Retrospective Studies; Topotecan; Treatment Outcome	2003
Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. British journal of cancer, 2003, Sep-15, Volume: 89, Issue:6 Topics: Antineoplastic Agents; Cost-Benefit Analysis; Doxorubicin; Drug Costs; Economics, Pharmaceutical; Female; Health Care Costs; Humans; Infusions, Intravenous; Liposomes; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Salvage Therapy; Spain; Topotecan	2003
Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Molecular cancer research : MCR, 2004, Volume: 2, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Ephrin-B2; Female; Fluorescein Angiography; Fluorescent Antibody Technique, Indirect; Humans; In Situ Hybridization; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Proteins; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proto-Oncogene Proteins c-sis; Receptor, Platelet-Derived Growth Factor beta; Topotecan; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; Wilms Tumor	2004
Recurrent ovarian cancer. Onkologie, 2004, Volume: 27, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure	2004
Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer. Gynecologic oncology, 2004, Volume: 93, Issue:1 Topics: Adolescent; Adult; Aged; Deoxycytidine; Drug Costs; Drug Resistance, Neoplasm; Female; Gemcitabine; Health Care Costs; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Topotecan	2004
The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecologic oncology, 2004, Volume: 94, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Genes, MDR; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Topotecan	2004
Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum? Gynecologic oncology, 2004, Volume: 94, Issue:2 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prognosis; Retrospective Studies; Topotecan	2004
Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecologic oncology, 2004, Volume: 95, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Topotecan	2004
The use of topotecan for relapsed ovarian cancer in accordance with the National Institute for Clinical Excellence Guidance 2001: the Nottingham experience. Clinical oncology (Royal College of Radiologists (Great Britain)), 2004, Volume: 16, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Medical Audit; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome	2004
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecologic oncology, 2005, Volume: 96, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Cell Line, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Topotecan; Xenograft Model Antitumor Assays	2005
Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecologic oncology, 2005, Volume: 98, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Topotecan	2005
Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma. Leukemia research, 2005, Volume: 29, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Salvage Therapy; Topotecan; Treatment Failure	2005
One- and two-stage designs for stratified phase II clinical trials. Statistics in medicine, 2005, Sep-15, Volume: 24, Issue:17 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cyclophosphamide; Data Interpretation, Statistical; Humans; Infant; Neoplasm Recurrence, Local; Neuroblastoma; Research Design; Topotecan	2005
p53 Gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma. Oncology, 2005, Volume: 69, Issue:2 Topics: Aged; Antineoplastic Agents; Carcinoma; Drug Resistance, Neoplasm; Female; Genes, p53; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polymerase Chain Reaction; Predictive Value of Tests; Retrospective Studies; Topotecan; Treatment Outcome	2005
Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease. Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chronic Disease; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Secondary Prevention; Topotecan	2005
Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer. Clinical lung cancer, 2005, Volume: 7, Issue:3 Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome	2005
CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecologic oncology, 2006, Volume: 103, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Retrospective Studies; Topotecan	2006
Oral second-line chemotherapy for advanced non-small-cell lung cancer: the bottom line. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18 Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Topotecan	2006
The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2005, Volume: 46, Issue:4 Topics: CA-125 Antigen; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Topotecan; Treatment Outcome	2005
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. Pediatric blood & cancer, 2008, Volume: 50, Issue:3 Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cerebral Ventricle Neoplasms; Combined Modality Therapy; Consciousness Disorders; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Etoposide; Female; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Hypophysectomy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pituitary Neoplasms; Temozolomide; Thiotepa; Topotecan	2008
Cerebral and parotid metachronous metastases from an ovarian carcinoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:11 Topics: Adenocarcinoma, Mucinous; Anticonvulsants; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Parotid Neoplasms; Supratentorial Neoplasms; Topotecan	2006
Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? Pediatric blood & cancer, 2007, Volume: 49, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Infection Control; Kaplan-Meier Estimate; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Postoperative Care; Retrospective Studies; Risk; Salvage Therapy; Sarcoma, Ewing; Topotecan; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vincristine	2007
Topotecan more effective than supportive care. The Lancet. Oncology, 2007, Volume: 8, Issue:1 Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Small Cell; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Palliative Care; Quality of Life; Survival Rate; Topotecan	2007
Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecologic oncology, 2008, Volume: 108, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Topotecan	2008
Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model. Gynecologic oncology, 2008, Volume: 108, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Endometrial Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Topotecan	2008
Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy. Oncology, 2007, Volume: 73, Issue:3-4 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Retrospective Studies; Survival Rate; Topotecan; Treatment Outcome	2007
Topotecan demonstrates significant activity in recurrent small-cell lung cancer. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:1 Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Topoisomerase I Inhibitors; Topotecan	1996
Second-line therapy. Nursing standard (Royal College of Nursing (Great Britain) : 1987), 1997, Feb-12, Volume: 11, Issue:21 Topics: Antineoplastic Agents; Camptothecin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan; Treatment Failure	1997
Treatment of recurrent ovarian cancer: increasing options--"recurrent" results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topotecan	1997
Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan. Gynecologic oncology, 1998, Volume: 69, Issue:2 Topics: Antineoplastic Agents; Carcinoma; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platelet Count; Thrombocytopenia; Topotecan	1998
Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan. Gynecologic oncology, 1998, Volume: 69, Issue:2 Topics: Antineoplastic Agents; Autoantibodies; Carcinoma; Female; Humans; Immunoelectrophoresis; Neoplasm Recurrence, Local; Neurons; Ovarian Neoplasms; Thrombocytopenia; Topotecan	1998
Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer chemotherapy and pharmacology, 1999, Volume: 43, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Biological Availability; Child; Child, Preschool; Female; Humans; Infant; Injections, Intravenous; Male; Neoplasm Recurrence, Local; Neoplasms; Topotecan	1999
Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer. Japanese journal of clinical oncology, 2001, Volume: 31, Issue:2 Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prospective Studies; Topotecan	2001
Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Follow-Up Studies; Humans; Infant; Multivariate Analysis; Neoplasm Recurrence, Local; Prognosis; Rhabdomyosarcoma; Soft Tissue Neoplasms; Survival Rate; Topotecan; Treatment Failure; Vincristine	2001
Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecologic oncology, 2001, Volume: 83, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Topotecan	2001
Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer, 2002, Apr-01, Volume: 94, Issue:7 Topics: Age Factors; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Epithelial Cells; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Topotecan	2002